Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy

Ferroptosis is associated with increased immunogenicity and favorable TIME subtypes. A–D, Compare the expression of ICD biomarker genes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. E, Examine the proportions of TIME subtypes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. F, OS analysis of patients based on TIME subtypes in the IMvigor210 cohort. G, OS analysis of patients based on cancer-immune phenotypes and ferroptosis levels in tumor tissue in the IMvigor210 cohort. *, P < 0.05; ***, P < 0.001. ANXA1, annexin A1; ATP8A2, ATPase phospholipid transporting 8A2; CALR, calreticulin; TPM, transcripts per million.